



Corteva Delivers Strong Fourth Quarter and Full-Year 2021 Results Led by Broad-Based Execution, Provides 2022 Guidance

WILMINGTON, Del., February 2, 2022 – Corteva, Inc. (NYSE: CTVA) ("Corteva" or the "Company") today reported financial results for the fourth quarter and 12 months ended December 31, 2021.

4Q 2021 Results Overview

	Net Sales	Income from Cont. Ops (After Tax)	EPS
GAAP vs. 4Q 2020	\$3.48B +8%	\$155M +57%	\$0.21 +62%
NON-GAAP vs. 4Q 2020	Organic ¹ Sales \$3.49B +9%	Operating EBITDA ¹ \$262M +11%	Operating EPS ¹ \$0.08 +100%

FY 2021 Results Overview

	Net Sales	Income from Cont. Ops (After Tax)	EPS
GAAP	\$15.65B	\$1.82B	\$2.44
vs. FY 2020	+10%	+141%	+149%
	Organic ¹ Sales	Operating EBITDA ¹	Operating EPS ¹
NON-GAAP	\$15.50B	\$2.58B	\$2.15
vs. FY 2020	+9%	+23%	+43%

Full-Year 2021 Highlights

- Full-year 2021 net sales increased 10% versus prior year. Organic¹ sales rose 9% in the same period. Sales increased in both Crop Protection and Seed segments and all regions grew on a reported and organic¹ basis as compared to 2020.
- Crop Protection net sales grew 12% and organic¹ sales increased 11% for the full year, led by double-digit sales gains in Latin America. Volume gains were driven by continued penetration of new products, including Enlist[™] and Arylex[™] herbicide and Isoclast[™] insecticide. Price gains reflected strong execution across all regions.
- Seed net sales and organic¹ sales grew 8% compared to the year-ago period, with notable gains in both Latin America and North America² driven by increased planted area, share gains and continued penetration of Enlist E3^{TM3} soybeans. Price was up 4% globally, led by continued execution on our price for value strategy.
- GAAP income and earnings per share (EPS) from continuing operations were \$1.82 billion and \$2.44 per share for the full-year 2021, respectively. Operating EBITDA¹ was \$2.58 billion, a 23% improvement over prior year on strong price execution and volume gains in all regions and both segments. Operating EPS¹ was \$2.15 per share.
- Corteva delivered cash flow from operations of \$2.7 billion for the year, reflecting earnings growth and working capital improvements, primarily from higher advanced payments from customers for the 2022 season.
- Management provided full-year 2022 guidance⁴ and expects net sales in the range of \$16.7 billion to \$17.0 billion.
 Operating EBITDA¹ is expected to be in the range of \$2.8 billion to \$3.0 billion, an increase of 9-16% compared to prior year. Operating EPS¹ for 2022 is expected to be in the range of \$2.30 to \$2.50 per share.

^{1.} Organic Sales, Operating EPS and Operating EBITDA are non-GAAP measures. See page A-6 for further discussion. 2. North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa. 3. Enlist E3[™] soybeans are jointly developed by Corteva Agriscience LLC and MS Technologies[™]. 4. The Company does not provide the most comparable GAAP measure on a forward-looking basis. See page 6 for further discussion. 5. Shares of the Company's common stock may be repurchased periodically in open-market or private transactions. The actual timing, number and value of shares repurchased under the Company's authorized share repurchase program will be determined by management at its discretion and will depend on a variety of factors including the market price of Corteva common stock, general market and economic conditions, applicable legal requirements and other business.



"I am pleased with Corteva's overall performance in 2021. Against the backdrop of strong agriculture markets and customer demand, our teams delivered solid performance in technology penetration, customer delivery and financial results. This performance is testimony to our innovative portfolios, strong market positions and the execution by our more than 20,000 employees worldwide.

Global agriculture fundamentals remain strong going into 2022, and we expect demand across the industry to remain resilient despite other macro challenges. We expect to deliver continued growth by advancing our market-leading technologies, while maintaining a focus on operational excellence. We also remain committed to a disciplined capital deployment strategy, which includes investing for future growth while returning cash to shareholders via dividends and share repurchases."

Chuck Magro Chief Executive Officer

Company Update

Company Drives Progress on Enlist[™] Weed Control System

- EPA completed the registration amendment process for Enlist One[®] and Enlist Duo[®] herbicides, which received a seven-year registration, giving farmers further confidence in the weed control system
- Anticipating continued high demand for Enlist™ system in U.S. markets for the 2022 season as market penetration is expected to reach at least 40% of U.S. soybean acres
- Delivered more than \$870 million in sales for Enlist™ system during 2021 – nearly double 2020 performance

High-Value Innovation Driving Market Share Gains

- Delivered sales increases on new Crop Protection products – up approximately \$450 million versus 2020, an increase of more than 40%
- New and differentiated Crop Protection product portfolio demonstrated ongoing strength globally in 2021, with 220 registration approvals spanning 27 active ingredients in 66 countries
- Customer demand for new and differentiated products drove organic¹ growth and share gains in key markets including U.S. Crop Protection, Pioneer[®] brand corn hybrids, soybean varieties, Brevant[®] brand corn, Brazil Safrinha and European sunflower

Pricing, Productivity and Supply Chain Execution Contribute to Margin Expansion

- Global pricing actions to capture the value of technology more than offset headwinds from market-driven cost inflation and logistical costs
- Global teams delivered approximately \$250 million in cost savings from productivity initiatives which contributed to margin expansion
- Crop Protection supply resiliency actions mitigated impacts from supply disruptions allowing the Company to meet customer demand with on-time deliveries and minimal impact to in-season demand

Accelerated Returns to Shareholders Reinforces Company's Commitment to Long-Term Value-Creation

- Returned more than \$1.3 billion to shareholders during 2021 via dividends and share repurchases
- Repurchased \$950 million in common stock during 2021 including completion of the 2019 \$1.0 billion share repurchase program
- The Company expects to deliver between \$1.0 billion and \$1.5 billion to shareholders in 2022, including both dividends and share repurchases⁵

Summary of Fourth Quarter 2021

For the fourth quarter ended December 31, 2021, net sales increased 8% versus the same period last year. Organic¹ sales rose 9%. Sales were led by double-digit gains in Latin America.

Volume grew 1% versus the prior-year period, with gains in both segments led by continued demand for our new and differentiated technologies, coupled with strong customer demand in Latin America. Volume gains were partially offset by the strategic decision to phase out select low-margin products, and supply constraints in North America Crop Protection.

Price increased 8% versus prior year. Higher prices in all regions helped to offset the impact of ongoing raw material

cost inflation and other market-driven headwinds.

Crop Protection net sales increased 6% for the quarter, primarily due to price execution.

Seed net sales rose 12% for the period, primarily driven by double-digit gains in Latin America on strong demand for corn and price execution across all regions.

GAAP income from continuing operations after income taxes was \$155 million for the fourth quarter of 2021. Operating EBITDA¹ for the period was \$262 million, up 11% compared to prior year.

				Organic ¹ Change
79	\$3,207	8%		9%
361	\$1,350	1%		1%
421	\$417	1%		-%
342	\$1,051	28%		28%
355	\$389	(9)%		(6)%
	79 361 421 342 355	361\$1,350421\$417342\$1,051	361\$1,3501%421\$4171%342\$1,05128%	361\$1,3501%421\$4171%342\$1,05128%

(\$ in millions, except where noted)	FY 2021	FY 2020	% Change	% Organic ¹ Change
Net Sales	\$15,655	\$14,217	10%	9%
North America	\$7,536	\$7,168	5%	4%
EMEA	\$3,123	\$2,842	10%	6%
Latin America	\$3,545	\$2,805	26%	27%
Asia Pacific	\$1,451	\$1,402	3%	3%

Crop Protection Summary

Crop Protection net sales were approximately \$2.1 billion in the fourth quarter of 2021 compared to approximately \$2.0 billion in the fourth quarter of 2020. The sales increase was driven by a 6% increase in price and a 1% increase in volume. These gains were partially offset by a 1% unfavorable portfolio impact.

The price increase was driven by gains in North America, including pricing for higher raw material and logistical costs. The increase in volume was driven by continued penetration of new and differentiated products, coupled with strong customer demand in Latin America. These volume gains were partially offset by an approximate \$75 million impact from the decision to phase out select low-margin products. The Company also encountered supply constraints in North America, resulting in an approximate \$70 million volume impact in the quarter.

The portfolio impact was driven by a divestiture in Asia Pacific.

Segment Operating EBITDA was \$305 million in the fourth quarter of 2021, down 7% from the fourth quarter of 2020. Continued price execution, productivity actions and volume gains from new products were more than offset by higher input costs, including raw material costs, volume impacts from supply constraints and higher variable compensation costs.

(\$ in millions, except where noted)	4Q 2021	4Q 2020	% Change	% Organic ¹ Change
North America	\$839	\$845	(1)%	(1)%
EMEA	\$220	\$211	4%	5%
Latin America	\$764	\$602	27%	27%
Asia Pacific	\$264	\$309	(15)%	(11)%
Total 4Q Crop Protection Net Sales	\$2,087	\$1,967	6%	7%

Crop Protection net sales were approximately \$7.3 billion for full-year 2021 compared to approximately \$6.5 billion in the prior year. The increase was due to a 6% increase in volume, a 5% increase in price and a 2% favorable impact from currency, partially offset by a 1% unfavorable portfolio impact.

Volume gains were led by continued penetration of new products globally, with combined sales of more than \$1.4 billion in 2021 – up nearly \$450 million compared to the prior-year period – led by Enlist[™] and Arylex[™] herbicides and Isoclast[™] insecticide. These volume gains were partially offset by an approximate \$275 million impact from our decision to phase out select low-margin products. The increase in price was primarily driven by gains in North America and Latin America, including pricing for higher raw material and logistical costs. Favorable currency impacts were primarily from the Euro. The portfolio impact was driven by a divestiture in Asia Pacific.

Segment Operating EBITDA was \$1.2 billion in 2021, up 20% from 2020. Pricing execution, continued penetration of new products, ongoing cost and productivity actions and a favorable impact from currency more than offset higher input costs, including raw material and logistical costs, and higher variable compensation costs. Segment Operating EBITDA margin improved by more than 100 basis points versus the prior-year period.

(\$ in millions, except where noted)	FY 2021	FY 2020	% Change	% Organic ¹ Change
North America	\$2,532	\$2,373	7%	6%
EMEA	\$1,524	\$1,374	11%	6%
Latin America	\$2,125	\$1,688	26%	26%
Asia Pacific	\$1,072	\$1,026	4%	4%
Total FY Crop Protection Net Sales	\$7,253	\$6,461	12%	11%

Seed Summary

Seed net sales were \$1.4 billion in the fourth quarter of 2021, up from \$1.2 billion in the fourth quarter of 2020. The increase was due to a 10% increase in price and a 2% increase in volume.

The increase in price was led by strong execution in Latin America and North America. Volume gains were driven by strong demand for corn in Latin America, led by Brazil. Segment Operating EBITDA was \$(11) million in the fourth quarter of 2021, an improvement of 77% from the fourth quarter of 2020. Continued price execution, ongoing cost and productivity actions, higher volumes and lower royalties more than offset higher input costs from higher commodity costs, higher variable compensation costs and a loss from the remeasurement of an equity investment.

(\$ in millions, except where noted)	4Q 2021	4Q 2020	% Change	% Organic ¹ Change
North America	\$522	\$505	3%	3%
EMEA	\$201	\$206	(2)%	(5)%
Latin America	\$578	\$449	29%	30%
Asia Pacific	\$91	\$80	14%	13%
Total 4Q Seed Net Sales	\$1,392	\$1,240	12%	12%

Seed net sales were approximately \$8.4 billion in 2021, up from approximately \$7.8 billion in the year-ago period. The increase was due to a 4% increase in price and a 4% increase in volume.

Local price gains were driven by strong adoption of new Seed technology, including price execution in Latin America and EMEA, with corn price up 5% globally. These gains were partially offset by competitive pricing pressure in North America soybeans, where price was down 2%. The increase in volume was driven by strong demand for corn in Brazil,

coupled with higher soybean and corn sales in North America.

Segment Operating EBITDA was \$1.5 billion in 2021, up 25% from the prior year. Continued price execution, volume gains, ongoing cost and productivity actions, lower royalties and lower bad debt expense more than offset higher input costs, higher freight and warehousing costs and higher variable compensation costs. Segment Operating EBITDA margin improved by more than 240 basis points versus the prior-year period.

(\$ in millions, except where noted)	FY 2021	FY 2020	% Change	% Organic ¹ Change
North America	\$5,004	\$4,795	4%	3%
EMEA	\$1,599	\$1,468	9%	6%
Latin America	\$1,420	\$1,117	27%	30%
Asia Pacific	\$379	\$376	1%	-%
Total FY Seed Net Sales	\$8,402	\$ 7,756	8%	8%

2022 Outlook

The Company provided guidance⁴ for the full-year 2022. Corteva expects net sales in the range of \$16.7 billion to \$17.0 billion, which at the mid-point represents expected net sales growth of 8% for the year and organic¹ sales growth of 11% for the year. Operating EBITDA¹ is expected to be in the range of \$2.8 billion to \$3.0 billion and operating EPS¹ range is expected to be between \$2.30 and \$2.50 per share. The Company is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of its control, such as Significant Items, without unreasonable effort.

Fourth Quarter and Full-Year Conference Call

The Company will host a live webcast of its fourth-quarter and full-year 2021 earnings conference call with investors to discuss its results and outlook tomorrow, February 3, 2022, at 9:00 a.m. ET. The slide presentation that accompanies the conference call is posted on the Company's Investor Events and Presentations page. A replay of the webcast will also be available on the <u>Investor</u> <u>Events and Presentations page</u>.

About Corteva

Corteva, Inc. (NYSE: CTVA) is a publicly traded, global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the Company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.

Follow Corteva on Facebook, Instagram, LinkedIn, Twitter, and YouTube.

Cautionary Statement About Forward-Looking Statements

This report contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates," "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's strategy for growth, product development, regulatory approvals, market position; capital allocation strategy; liquidity; environmental, social and governance ("ESG") targets; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters, expenditures, and financial results are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition. Some of the important factors that could cause Corteva's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to successfully develop and commercialize Corteva's pipeline; (ii) failure to obtain or maintain the necessary regulatory approvals for some of Corteva's products; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) effect of competition and consolidation in Corteva's industry; (vi) effect of competition from manufacturers of generic products; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) failure to comply with competition and anti-trust laws; (x) capital markets sentiment towards ESG matters (xi) competitor's establishment of an intermediary platform for distribution of Corteva's products; (xii) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xiii) effect of industrial espionage and other disruptions to Corteva's supply chain, information technology or network systems; (xiv) effect of volatility in Corteva's input costs; (xv) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xvi) failure of Corteva's customers to pay their debts to Corteva, including customer financing programs; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) risks related to environmental litigation and the indemnification obligations of legacy EID liabilities in connection with the separation of Corteva; (xix) risks related to Corteva's global operations; (xx) failure to effectively manage acquisitions, divestitures, alliances cost savings initiatives, and other portfolio actions; (xxi) risks related to COVID-19; (xxii) Corteva's ability to recruit and retain key personnel; (xxiii) Corteva's intellectual property rights or defend against intellectual property claims asserted by others; (xxiv) effect of counterfeit products; (xxv) Corteva's dependence on intellectual property cross-license agreements; (xxvi) other risks related to the Separation from DowDuPont.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.

Regulation G (Non-GAAP Financial Measures)

This earnings release includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include organic sales, organic growth (including by segment and region), operating EBITDA, operating earnings per share, and base tax rate. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results. These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page A-5 of the Financial Statement Schedules.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as Significant Items, without unreasonable effort. For Significant items reported in the periods presented, refer to page A-10 of the Financial Statement Schedules. Beginning January 1, 2020, the Company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the noncash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® Roundup Ready 2 Xtend® herbicide tolerance traits. During the five-year ramp-up period of Enlist E3TM, Corteva is expected to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. During the five-year ramp-up period of Enlist E3TM, Corteva is expected to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform after the completion of the ramp-up. Organic sales is defined as price and volume and excludes currency and portfolio impacts. Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs) and foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating (benefits) costs of non-operating pension and other post-employment benefit (OPEB) benefits (costs), tax indemnification adjustments, environmental remediatio

Operating earnings (loss) per share are defined as "Earnings (loss) per common share from continuing operations – diluted" excluding the after-tax impact of significant items, the after tax impact of non-operating benefits (costs), and the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the net gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts without the resulting unrealized mark to fair value volatility. Base tax rate is defined as the effective tax rate excluding the impacts of foreign exchange gains (losses) net, non-operating benefits (costs), amortization of intangibles as of the Separation from DowDuPont, and significant items.

® TM Corteva Agriscience and its affiliated companies.

02/02/2022

Media Contact

Kasey Anderson +1 317-337-4478 kasey.anderson@corteva.com

Investor Contact

Jeff Rudolph +1 302-485-3704 jeff.rudolph@corteva.com



Corteva, Inc. **Consolidated Statements of Operations** (Dollars in millions, except per share amounts)

	Three Months Ended December 31,			Twelve Montl Decembe				
		2021		2020		2021		2020
Net sales	\$	3,479	\$	3,207	\$	15,655	\$	14,217
Cost of goods sold		2,232		2,112		9,220		8,507
Research and development expense		316		305		1,187		1,142
Selling, general and administrative expenses		806		724		3,209		3,043
Amortization of intangibles		179		181		722		682
Restructuring and asset related charges - net		28		37		289		335
Other income - net		335		92		1,348		212
Interest expense		8		10		30		45
Income (loss) from continuing operations before income taxes		245		(70)		2,346		675
Provision for (benefit from) from income taxes on continuing operations		90		(169)		524		(81)
Income (loss) from continuing operations after income taxes		155		99		1,822		756
Income (loss) from discontinued operations after income taxes		6		(56)		(53)		(55)
Net income (loss)		161		43		1,769		701
Net income (loss) attributable to noncontrolling interests		2		2		10		20
Net income (loss) attributable to Corteva	\$	159	\$	41	\$	1,759	\$	681
Basic earnings (loss) per share of common stock:								
Basic earnings (loss) per share of common stock from continuing operations	\$	0.21	\$	0.13	\$	2.46	\$	0.98
Basic earnings (loss) per share of common stock from discontinued operations		0.01		(0.08)		(0.07)		(0.07)
Basic earnings (loss) per share of common stock	\$	0.22	\$	0.05	\$	2.39	\$	0.91
Diluted earnings (loss) per share of common stock:								
Diluted earnings (loss) per share of common stock from continuing operations	\$	0.21	\$	0.13	\$	2.44	\$	0.98
Diluted earnings (loss) per share of common stock from discontinued operations		0.01		(0.08)		(0.07)		(0.07)
Diluted earnings (loss) per share of common stock	\$	0.22	\$	0.05	\$	2.37	\$	0.91
Average number of shares outstanding used in earnings (loss) per share (EPS) calculation (in millions)								
Basic		729.2		746.3		735.9		748.7
Diluted		735.1		749.7		741.6		751.2

A-2

Corteva, Inc.

Consolidated Balance Sheets

(Dollars in millions, except per share amounts)

	Dec	ember 31, 2021	December 31, 2020	
Assets				
Current assets				
Cash and cash equivalents	\$	4,459	\$	3,526
Marketable securities		86		269
Accounts and notes receivable, net		4,811		4,926
Inventories		5,180	4	4,882
Other current assets		1,010	1	1,165
Total current assets		15,546	14	4,768
Investment in nonconsolidated affiliates		76		66
Property, plant and equipment		8,364	8	8,253
Less: Accumulated depreciation		4,035	2	3,857
Net property, plant and equipment		4,329	2	4,396
Goodwill		10,107	10	0,269
Other intangible assets		10,044	10	0,747
Deferred income taxes		438		464
Other assets		1,804	1	1,939
Total Assets	\$	42,344	\$ 42	2,649
Liabilities and Equity				
Current liabilities				
Short-term borrowings and finance lease obligations	\$	17	\$	3
Accounts payable		4,126		3,615
Income taxes payable		146		123
Deferred revenue		3,201	2	2,662
Accrued and other current liabilities		2,068		2,145
Total current liabilities		9,558		8,548
Long-term debt		1,100		1,102
Other noncurrent liabilities		1,100		,102
Deferred income tax liabilities		1,220		893
Pension and other post employment benefits - noncurrent		3,124	4	5,176
Other noncurrent obligations		1,719		1,867
Total noncurrent liabilities		7,163		9,038
Commitments and contingent liabilities				
Commence and contingent natinties				
Stockholders' equity				
Common stock, \$0.01 par value; 1,666,667,000 shares authorized; issued at December 31, 2021 - 726,527,000 and December 31, 2020 - 743,458,000		7		7
Additional paid-in capital		27,751	27	7,707
Retained earnings (accumulated deficit)		524		—
Accumulated other comprehensive income (loss)		(2,898)	(2	2,890)
Total Corteva stockholders' equity		25,384		4,824
Noncontrolling interests		239		239
Total equity		25,623	25	5,063
Total Liabilities and Equity	\$	42,344		2,649

A-3 Corteva, Inc. Consolidated Statements of Cash Flows (Dollars in millions, except per share amounts)

Querating activities20212020Operating activitiesNet memor (loss)\$1,769\$701Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities12,431,177Provision for (benefit from) deferred income tax174(330)Net periodic pension and OPEB benefit, net(1,222)(340)Pension and OPEB contributions(21)3Restructuring and asset related charges - net289335Other net loss1052000Charges in operating assets and liabilities, net(113)187Accounts and notes receivable(113)187Inventories(422)1044Accounts and notes receivable(113)187Other assets and liabilities, net2322040Accounts payable2,7272,0044Deferred revenue2,7272,0044Deferred revenue2,7272,0044Investrories(73)(73)Other assets and liabilities93233Cash provided by (used for) operating activities(53)(75)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested(10)(10)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested(36)(77)Other assets and inabilities, net(20)(77)Other investing activities, net(20)(77)Other investing activities, net(20)(77)Other investing activities <t< th=""><th></th><th colspan="5">Twelve Months Ended December 31,</th></t<>		Twelve Months Ended December 31,				
Net income (loss) \$ 1,769 \$ 701 Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities			2021		2020	
Adjustments to reconcile net income (loss) to eash provided by (used for) operating activities 1.243 1.177 Provision for (benefit from) deferred income tax 174 (330) Net periodic pension and OPEB benefit, net (1.292) (340) Pension and OPEB contributions (247) (269) Net (gain) loss on sales of property, businesses, consolidated companies, and investments (21) 3 Restructuring and asset related charges - net 289 335 Other net loss 156 290 Changes in operating assets and liabilities, net (113) 187 Inventories 4(422) 104 Accounts and notes receivable (118) 187 Inventories 232 233 Cash provided by (used for) operating activities 2,727 2,064 Accounts and notes receivable 71 0 Other assets and liabilities 93 253 Cash provided by (used for) operating activities 2,727 2,064 Investing activities (362) (673) (475) Proceeds from sales of property, businesses, and consolidated companies	Operating activities					
Depreciation and amortization1,2431,177Provision for (benefit from) deferred income tax174(330)Net periodic pension and OPEB benefit, net(1,292)(340)Pension and OPEB contributions(247)(269)Net (gain) loss on sales of property, businesses, consolidated companies, and investments(21)3Restructuring and asset related charges - net289335Other net loss156290Charges in operating assets and liabilities, net(113)187Accounts and notes receivable(113)187Inventories(422)104Accounts payable524(118)Deferred revenue57471Other assets and liabilities93253Cash provided by (used for) operating activities2,7272,064Investing activities2,7272,064Investing activities(573)(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested(1)(1)Other assets and maturities of investments(362)(674)Investments in and loans to nonconsolidated affiliates(4)(1)Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities, net(1)(7)Proceeds from sales and maturities of investments(36)(Net income (loss)	\$	1,769	\$	701	
Provision for (benefit from) deferred income tax174(330)Net periodic pension and OPEB benefit, net(1,292)(340)Pension and OPEB contributions(247)(269)Net (gain) loss on sules of property, businesses, consolidated companies, and investments(21)3Restructuring and asset related charges - net2893355Other net loss156290Charges in operating assets and liabilities, net(113)187Inventories(422)104Accounts payable524(118)Deferred revenue57471Other assets and liabilities93253Cash provided by (used for) operating activities2,7272,064Investing activities2,7272,064Investing activities2,7272,064Investing activities2,7272,064Investing activities2,7272,064Investing activities2,7272,064Investing activities2,7272,064Investing activities2,0292,335Investing activities2,0314,355Investing activities3,3553,355Investing activities3,3553,355Investing activities of investing activities3,3553,355Investing activities, net(11)(7)Cash provided by (used for) investing activities3,3553,355Investing activities, net(11)(7)Proceeds from alse and maturities of investing activities3,3553,355<	Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities					
Net periodic pension and OPEB benefit, net (1,292) (340) Pension and OPEB contributions (247) (269) Net (gain) loss on sales of property, businesses, consolidated companies, and investments (21) 3 Restructuring and asset related charges - net 289 3335 Other net loss 156 290 Charges in operating assets and liabilities, net (113) 187 Inventories (422) 104 Accounts payable 524 (118) Deferred revenue 574 71 Other assets and liabilities 93 253 Cash provided by (used for) operating activities 2,727 2,064 Investing activities (573) (475) Proceeds from sales of property, businesses, and consolidated companies - net of cash 75 83	Depreciation and amortization		1,243		1,177	
Pension and OPEB contributions (247) (269) Net (gain) loss on sales of property, businesses, consolidated companies, and investments (21) 3Restructuring and asset related charges - net289335Other net loss156290Changes in operating assets and liabilities, net(113)187Inventories (422) 104Accounts payable524(118)Deferred revenue57471Other assets and liabilities93253Cash provided by (used for) operating activities2,7272,064Investing activities2,7272,064Investing activities(673)(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investing activities, net(11)(1)Proceeds from sales and maturities of investments3457211Other investing activities, net(1)(1)Other investing activities, net(362)(674)Financing activities(362)(674)Financing activities(362)(674)Proceeds from exers of stock options13Proceeds from exers of stock options10056Diverding activities, net(950)(275)Proceeds from exers of stock options10056Diverding activities, net(30)(28)Payments on debt(497)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest-	Provision for (benefit from) deferred income tax		174		(330)	
Net (gain) loss on sales of property, businesses, consolidated companies, and investments(21)3Restructuring and asset related charges - net289335Other net loss156290Changes in operating assets and liabilities, net(113)187Inventories(422)104Accounts and notes receivable(113)187Inventories(422)104Accounts payable524(118)Deferred revenue57471Other assets and liabilities93253Cash provided by (used for) operating activities2,7272,064Investing activities(573)(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested(11)(7)Cash provided by (used for) investing activities(362)(674)Finacing activities, net(11)(7)Cash provided by (used for) investing activities(362)(674)Finacing activities(352)(674)Finacing activities(362)(674)Finacing activities(30)(255)Proceeds from debt(419)2,439Payment on debt(421)(1,441)Repurchase of occk options10056Dividends paid to stockholders(397) <td>Net periodic pension and OPEB benefit, net</td> <td></td> <td>(1,292)</td> <td></td> <td>(340)</td>	Net periodic pension and OPEB benefit, net		(1,292)		(340)	
Restructuring and asset related charges - net 289 335 Other net loss 156 290 Changes in operating assets and liabilities, net (113) 187 Accounts and notes receivable (113) 187 Inventories (422) 104 Accounts payable 524 (118) Defered revenue 574 71 Other assets and liabilities 93 253 Cash provided by (used for) operating activities 2,727 2,064 Investing activities 1,01 (1) Proceeds from sales of property, businesses, and consolidated companies - net of cash divested 11	Pension and OPEB contributions		(247)		(269)	
Other net loss 156 290 Changes in operating assets and liabilities, net (113) 187 Accounts and notes receivable (113) 187 Inventories (422) 104 Accounts payable 524 (118) Deferred revenue 574 71 Other assets and liabilities 93 253 Cash provided by (used for) operating activities 2,727 2,064 Investing activities 2,737 2,064 Investing activities 2,727 2,064 Investing activities 2,727 2,064 Investing activities 2,727 2,064 Investing activities 75 83 Investing activities 101 <td>Net (gain) loss on sales of property, businesses, consolidated companies, and investments</td> <td></td> <td>(21)</td> <td></td> <td>3</td>	Net (gain) loss on sales of property, businesses, consolidated companies, and investments		(21)		3	
Changes in operating assets and liabilities, netAccounts and notes receivable(113)187Inventories(422)104Accounts payable524(118)Deferred revenue57471Other assets and liabilities93253Cash provided by (used for) operating activities2,7272,064Investing activities2,7272,064Investing activities(173)(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales and maturities of investments(204)(995)Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)Financing activities(352)(674)Proceeds from sales and maturities of investments(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)(141)Repurchase of common stock(955)(275)Proceeds from debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest— </td <td>Restructuring and asset related charges - net</td> <td></td> <td>289</td> <td></td> <td>335</td>	Restructuring and asset related charges - net		289		335	
Accounts and notes receivable(113)187Inventories(422)104Accounts payable524(118)Deferred revenue57471Other assets and liabilities93253Cash provided by (used for) operating activities2,7272,064Investing activities2,7272,064Capital expenditures(573)(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)Financing activities13—Proceeds from soles of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(130)(28)	Other net loss		156		290	
Inventories (42) 104 Accounts payable 524 (118) Deferred revenue 574 71 Other assets and liabilities 93 253 Cash provided by (used for) operating activities $2,727$ $2,064$ Investing activities $2,727$ $2,064$ Investing activities $2,727$ $2,064$ Investing activities (573) (475) Proceeds from sales of property, businesses, and consolidated companies - net of cash divested 75 83 Investments in and loans to nonconsolidated affiliates (4) (1) Purchases of investments (204) (995) Proceeds from sales and maturities of investments 345 721 Other investing activities, net (1) (7) Cash provided by (used for) investing activities (362) (674) Financing activities 419 $2,439$ Payments on debt 419 $2,439$ Payments on debt (421) $(1,441)$ Repurchase of common stock (950) (275) Proceeds from exercise of stock options 100 56 Dividends paid to stockholders (397) (388) Payment for acquisition of subsidiary's interest from the non-controlling interest $ (60)$ Other financing activities, net (30) (28) Cash provided by (used for) financing activities $(1,266)$ 303	Changes in operating assets and liabilities, net					
Accounts payable524(118)Deferred revenue57471Other assets and liabilities93253Cash provided by (used for) operating activities2,7272,064Investing activities2,7272,064Investing activities2,7272,064Investing activities6,573(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)Proceeds from debt4192,439Payments on debt(421)(1,141)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Accounts and notes receivable		(113)		187	
Deferred revenue57471Other assets and liabilities93253Cash provided by (used for) operating activities2,7272,064Investing activities2,7272,064Investing activities(573)(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(1)(7)Cash provided by (used for) investing activities13Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Inventories		(422)		104	
Other assets and liabilities93253Cash provided by (used for) operating activities $2,727$ $2,064$ Investing activities(573)(475)Capital expenditures(573)(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(303)(28)	Accounts payable		524		(118)	
Cash provided by (used for) operating activities2,7272,064Investing activities(573)(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities13-Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest-(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(303)(28)	Deferred revenue		574		71	
Investing activitiesCapital expenditures(573)(475)Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities13Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1266)303	Other assets and liabilities		93		253	
Capital expenditures (573) (475) Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates (4) (1) Purchases of investments (204) (995) Proceeds from sales and maturities of investments345 721 Other investing activities, net (1) (7) Cash provided by (used for) investing activities (362) (674) Financing activities13-Proceeds from debt4192,439Payments on debt (421) $(1,441)$ Repurchase of common stock (950) (275) Proceeds from exercise of stock options10056Dividends paid to stockholders (397) (388) Payment for acquisition of subsidiary's interest from the non-controlling interest- (60) Other financing activities, net (30) (28) Cash provided by (used for) financing activities $(1,266)$ 303	Cash provided by (used for) operating activities		2,727		2,064	
Proceeds from sales of property, businesses, and consolidated companies - net of cash divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)Functing activities(1)(7)Cash provided by (used for) investing activities(362)(674)Functing activities(362)(674)Functing activities(362)(674)Functing activities(362)(674)Proceeds from debt(1)(7)Proceeds from debt(1)(7)Proceeds from debt(21)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303						
divested7583Investments in and loans to nonconsolidated affiliates(4)(1)Purchases of investments(204)(995)Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)Financing activities(362)(674)Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Capital expenditures		(573)		(475)	
Purchases of investments(204)(995)Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)Financing activities(362)(674)Proceeds from debt13—Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303			75		83	
Proceeds from sales and maturities of investments345721Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)Net change in borrowings (less than 90 days)13—Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Investments in and loans to nonconsolidated affiliates		(4)		(1)	
Other investing activities, net(1)(7)Cash provided by (used for) investing activities(362)(674)Financing activities(362)(674)Net change in borrowings (less than 90 days)13—Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Purchases of investments		(204)		(995)	
Cash provided by (used for) investing activities(362)(674)Financing activitiesNet change in borrowings (less than 90 days)13—Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Proceeds from sales and maturities of investments		345		721	
Financing activitiesNet change in borrowings (less than 90 days)13—Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Other investing activities, net		(1)		(7)	
Financing activitiesNet change in borrowings (less than 90 days)13—Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Cash provided by (used for) investing activities		(362)		(674)	
Proceeds from debt4192,439Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Financing activities					
Payments on debt(421)(1,441)Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Net change in borrowings (less than 90 days)		13		_	
Repurchase of common stock(950)(275)Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Proceeds from debt		419		2,439	
Proceeds from exercise of stock options10056Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Payments on debt		(421)		(1,441)	
Dividends paid to stockholders(397)(388)Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Repurchase of common stock		(950)		(275)	
Payment for acquisition of subsidiary's interest from the non-controlling interest—(60)Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Proceeds from exercise of stock options		100		56	
Other financing activities, net(30)(28)Cash provided by (used for) financing activities(1,266)303	Dividends paid to stockholders		(397)		(388)	
Cash provided by (used for) financing activities (1,266) 303	Payment for acquisition of subsidiary's interest from the non-controlling interest				(60)	
• • • • • •	Other financing activities, net		(30)		(28)	
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents (136) 7	Cash provided by (used for) financing activities		(1,266)		303	
	Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents		(136)		7	
Increase (decrease) in cash, cash equivalents and restricted cash equivalents 963 1,700	Increase (decrease) in cash, cash equivalents and restricted cash equivalents	_	963		1,700	
Cash, cash equivalents and restricted cash equivalents at beginning of period 3,873 2,173			3,873		2,173	
Cash, cash equivalents and restricted cash equivalents at end of period\$4,836\$3,873	Cash, cash equivalents and restricted cash equivalents at end of period	\$	4,836	\$	3,873	

A-4 Corteva, Inc. Consolidated Segment Information (Dollars in millions, except per share amounts)

	Three Months Ended December 31,					Twelve Months Ender December 31,			
SEGMENT NET SALES - SEED	2021			2020		2021	2020		
Corn	\$	1,113	\$	958	\$	5,618	\$	5,182	
Soybean		74		63		1,568		1,445	
Other oilseeds		91		90		752		619	
Other		114		129		464		510	
Seed	\$	1,392	\$	1,240	\$	8,402	\$	7,756	

	Three Months Ended December 31,						Twelve Months Ended December 31,			
SEGMENT NET SALES - CROP PROTECTION			2020		2021	2020				
Herbicides	\$	1,078	\$	965	\$	3,815	\$	3,280		
Insecticides		469		546		1,730		1,764		
Fungicides		399		318		1,310		1,032		
Other		141		138		398		385		
Crop Protection	\$	2,087	\$	1,967	\$	7,253	\$	6,461		

	Т	Three Months Ended December 31,					nths ber 3	Ended 31,
GEOGRAPHIC NET SALES - SEED		2021	2020			2021	2020	
North America ¹	\$	522	\$	505	\$	5,004	\$	4,795
EMEA ²		201		206		1,599		1,468
Latin America		578		449		1,420		1,117
Asia Pacific		91		80		379		376
Rest of World ³		870		735		3,398		2,961
Net Sales	\$	1,392	\$	1,240	\$	8,402	\$	7,756

	1	Three Mon Decem	unava		Twelve Mo Decem			
GEOGRAPHIC NET SALES - CROP PROTECTION	2021			2020		2021		2020
North America ¹	\$	839	\$	845	\$	2,532	\$	2,373
EMEA ²		220		211		1,524		1,374
Latin America		764		602		2,125		1,688
Asia Pacific		264		309		1,072		1,026
Rest of World ³		1,248		1,122		4,721		4,088
Net Sales	\$	2,087	\$	1,967	\$	7,253	\$	6,461

1. Reflects U.S. & Canada

2. Reflects Europe, Middle East, and Africa

3. Reflects EMEA, Latin America, and Asia Pacific

A-5 Corteva, Inc. **Reconciliation of Non-GAAP Measures** (Dollars in millions, except per share amounts)

	onths Ended ember 31,	e Months Ended ecember 31,
	2021	2021
Net Sales (GAAP)	\$ 3,479	\$ 15,655
Less: Impacts from Currency and Portfolio	(8)	154
Organic Sales (Non-GAAP)	\$ 3,487	\$ 15,501

	 Three Months Ended December 31,						Ended 31,
OPERATING EBITDA	2021		2020		2021		2020
Seed	\$ (11)	\$	(47)	\$	1,512	\$	1,208
Crop Protection	305		327		1,202		1,004
Corporate Expenses	(32)		(44)		(138)		(125)
Operating EBITDA (Non-GAAP)	\$ 262	\$	236	\$	2,576	\$	2,087

<u>RECONCILIATION OF INCOME (LOSS) FROM CONTINUING</u> OPERATIONS AFTER INCOME (LOSS) TAXES TO OPERATING	Three Mon Decem		Twelve Months Ended December 31,				
EBITDA	 2021	2020	2021			2020	
Income (loss) from continuing operations after income taxes (GAAP)	\$ 155	\$ 99	\$	1,822	\$	756	
Provision for (benefit from) income taxes on continuing operations	90	(169)		524		(81)	
Income (loss) from continuing operations before income taxes (GAAP)	245	 (70)		2,346		675	
Depreciation and amortization	317	309		1,243		1,177	
Interest income	(19)	(18)		(77)		(56)	
Interest expense	8	10		30		45	
Exchange (gains) losses - net ¹	7	47		54		174	
Non-operating (benefits) costs ²	(315)	(79)		(1,256)		(316)	
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges ³	(3)			_			
Significant items (benefits) charge ⁴	22	37		236		388	
Operating EBITDA (Non-GAAP)	\$ 262	\$ 236	\$	2,576	\$	2,087	

Refer to page A-15 for pre-tax and after tax impacts of exchange losses (gains) - net. 1.

Operating EBITDA (Non-GAAP)

2. Non-operating (benefits) costs consists of non-operating pension and other post-employment benefit (OPEB) (benefits) costs, tax indemnification adjustments, environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont, and the 2021 officer indemnification payment. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense.

Effective January 1, 2021, on a prospective basis, the Company excludes net unrealized gain or loss from mark-to-market activity for 3. certain foreign currency derivative instruments that do not qualify for hedge accounting. For the three and twelve months ended December 31, 2020, the unrealized mark-to-market loss was \$19 and \$0, respectively.

Refer to page A-10 for pre-tax and after tax impacts of significant items. 4.

A-6 Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

PRICE - VOLUME - CURRENCY ANALYSIS

REGION

			Q4 2021 vs.	Q4 2020		Percent Change Due To:							
	Net Sales Change (GAAP)		8 8 8		Price &			Portfolio /					
		\$	%	\$	%	Product Mix	Volume	Currency	Other				
North America	\$	11	1 % \$	11	1 %	9 %	(8)%	— %	— %				
EMEA		4	1 %	(1)	- %	3 %	(3)%	1 %	%				
Latin America		291	28 %	294	28 %	11 %	17 %	<u> %</u>	— %				
Asia Pacific		(34)	(9)%	(23)	(6)%	1 %	(7)%	%	(3)%				
Rest of World		261	14 %	270	15 %	7 %	8 %	— %	(1)%				
Total	\$	272	8 % \$	281	9 %	8 %	1 %	%	(1)%				

<u>SEED</u>

			Q4 2021 vs.	Q4 2020		Percent Change Due To:						
	Net Sales Change (GAAP)		Organic Change ¹ (Non-GAAP)		Price &			Portfolio /				
		\$	%	\$	%	Product Mix	Volume	Currency	Other			
North America	\$	17	3 % \$	16	3 %	5 %	(2)%	<u> %</u>	%			
EMEA		(5)	(2)%	(11)	(5)%	5 %	(10)%	3 %	— %			
Latin America		129	29 %	133	30 %	20 %	10 %	(1)%	%			
Asia Pacific		11	14 %	10	13 %	5 %	8 %	1 %	%			
Rest of World		135	18 %	132	18 %	14 %	4 %	<u> %</u>	<u> </u>			
Total	\$	152	12 % \$	148	12 %	10 %	2 %	%	— %			

CROP PROTECTION

			Q4 2021 vs.	Q4 2020		Percent Change Due To:						
	Net Sales Change (GAAP)		8 8 8		Price &			Portfolio /				
		\$	%	\$	%	Product Mix	Volume	Currency	Other			
North America	\$	(6)	(1)% \$	(5)	(1)%	11 %	(12)%	— %	<u> </u>			
EMEA		9	4 %	10	5 %	1 %	4 %	(1)%	%			
Latin America		162	27 %	161	27 %	5 %	22 %	<u> %</u>	%			
Asia Pacific		(45)	(15)%	(33)	(11)%	<u> %</u>	(11)%	<u> </u>	(4)%			
Rest of World		126	11 %	138	12 %	3 %	9 %	— %	(1)%			
Total	\$	120	6 % \$	133	7 %	6 %	1 %	%	(1)%			

A-7 Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

SEED PRODUCT LINE

		Q4 2021 vs.	Q4 2020			Percent Char	ge Due To:	
	Net Sales ((GAA	0	Organic Cl (Non-GA	0	Price &			Portfolio /
	\$	%	\$	%	Product Mix	Volume	Currency	Other
Corn	\$ 155	16 % \$	154	16 %	11 %	5 %	<u> %</u>	<u> </u>
Soybeans	11	17 %	9	14 %	16 %	(2)%	3 %	%
Other oilseeds	1	1 %	_	%	10 %	(10)%	1 %	<u> </u>
Other	(15)	(12)%	(15)	(12)%	4 %	(16)%	<u> %</u>	%
Total	\$ 152	12 % \$	148	12 %	10 %	2 %	<u> </u>	<u> </u>

CROP PROTECTION PRODUCT LINE

			Q4 2021 vs.	Q4 2020		Percent Change Due To:							
	Net Sales Change (GAAP)Organic Cl (Non-GA)		0	Price &			Portfolio /						
		\$	%	\$	%	Product Mix	Volume	Currency	Other				
Herbicides	\$	113	12 % \$	116	12 %	15 %	(3)%	%	%				
Insecticides		(77)	(14)%	(74)	(14)%	(2)%	(12)%	<u> %</u>	%				
Fungicides		81	25 %	88	28 %	5 %	23 %	<u> %</u>	(3)%				
Other		3	2 %	3	2 %	(18)%	20 %	<u> %</u>	%				
Total	\$	120	6 % \$	133	7 %	6 %	1 %	— %	(1)%				

A-8 Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

PRICE - VOLUME - CURRENCY ANALYSIS

REGION

]	Fwelve Mor	nths 2021 vs. T	welve Mon	ths 2020		Percent Chan	ge Due To:	
	Net Sales Change (GAAP)		0 0 0		Price &			Portfolio /	
		\$	%	\$	%	Product Mix	Volume	Currency	Other
North America	\$	368	5 % \$	307	4 %	2 %	2 %	1 %	<u> %</u>
EMEA		281	10 % \$	168	6 %	3 %	3 %	4 %	<u> %</u>
Latin America		740	26 % \$	767	27 %	10 %	17 %	(1)%	<u> </u>
Asia Pacific		49	3 % \$	43	3 %	2 %	1 %	2 %	(2)%
Rest of World		1,070	15 %	978	14 %	6 %	8 %	2 %	(1)%
Total	\$	1,438	10 % \$	1,285	9 %	4 %	5 %	1 %	<u> %</u>

<u>SEED</u>

]	Fwelve Mor	nths 2021 vs. [Fwelve Mon	ths 2020	Percent Change Due To:							
		Net Sales ((GAA	0	Organic C (Non-GA	0	Price &			Portfolio /				
		\$	%	\$	%	Product Mix	Volume	Currency	Other				
North America	\$	209	4 % \$	164	3 %	1 %	2 %	1 %	%				
EMEA		131	9 %	86	6 %	5 %	1 %	3 %	— %				
Latin America		303	27 %	336	30 %	16 %	14 %	(3)%	<u> </u>				
Asia Pacific		3	1 %	(1)	— %	2 %	(2)%	1 %	%				
Rest of World		437	15 %	421	14 %	9 %	5 %	1 %	— %				
Total	\$	646	8 % \$	585	8 %	4 %	4 %	— %	<u> %</u>				

CROP PROTECTION

	Twelve Mor	nths 2021 vs. 7	Fwelve Mon	ths 2020		Percent Change Due To:					
	Net Sales ((GAA	0	Organic Change ¹ (Non-GAAP)		Price &			Portfolio /			
	\$	%	\$	%	Product Mix	Volume	Currency	Other			
North America	\$ 159	7 % \$	143	6 %	6 %	%	1 %	<u> </u>			
EMEA	150	11 %	82	6 %	2 %	4 %	5 %	%			
Latin America	437	26 %	431	26 %	7 %	19 %	<u> %</u>	%			
Asia Pacific	46	4 %	44	4 %	1 %	3 %	3 %	(3)%			
Rest of World	633	15 %	557	14 %	4 %	10 %	2 %	(1)%			
Total	\$ 792	12 % \$	700	11 %	5 %	6 %	2 %	(1)%			

A-9 Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

SEED PRODUCT LINE

	,	Twelve Mon	ths 2021 vs. 1	Fwelve Mon	ths 2020		ge Due To:		
		Net Sales ((GAA)	0	Organic C (Non-GA	0	Price &			Portfolio /
		\$	%	\$	%	Product Mix	Volume	Currency	Other
Corn	\$	436	8 % \$	413	8 %	5 %	3 %	— %	— %
Soybeans		123	9 %	104	7 %	— %	7 %	2 %	— %
Other oilseeds		133	21 %	117	19 %	5 %	14 %	2 %	<u> </u>
Other		(46)	(9)%	(49)	(10)%	(2)%	(8)%	1 %	<u> </u>
Total	\$	646	8 % \$	585	8 %	4 %	4 %	— %	— %

CROP PROTECTION PRODUCT LINE

	,	Twelve Mon	ths 2021 vs. 7	Fwelve Mont	hs 2020	Percent Change Due To:							
		Net Sales C (GAAl	0	Organic Cl (Non-GA	8	Price &			Portfolio /				
		\$	%	\$	%	Product Mix	Volume	Currency	Other				
Herbicides	\$	535	16 % \$	465	14 %	7 %	7 %	2 %	<u> </u>				
Insecticides		(34)	(2)%	(50)	(3)%	2 %	(5)%	1 %	%				
Fungicides		278	27 %	272	26 %	4 %	22 %	3 %	(2)%				
Other		13	3 %	13	3 %	(8)%	11 %	%	%				
Total	\$	792	12 % \$	700	11 %	5 %	6 %	2 %	(1)%				

1. Organic sales is defined as price and volume and excludes currency and portfolio impacts.

A-10 Corteva, Inc. Significant Items (Dollars in millions, except per share amounts)

SIGNIFICANT ITEMS BY SEGMENT (PRE-TAX)

	Three Mon Decem		Twelve Months Ended December 31,					
	2021	2020		2021		2020		
Seed	\$ —	\$ (11)	\$	(98)	\$	(165)		
Crop Protection	(9)	(11)		(60)		(162)		
Corporate	(13)	(15)		(78)		(61)		
Total significant items before income taxes	\$ (22)	\$ (37)	\$	(236)	\$	(388)		

SIGNIFICANT ITEMS - PRE-TAX, AFTER TAX, AND EPS IMPACTS

	Pre	-tax			After	• tax ⁸		(\$ Per Share)			
2	2021	2	2020	2	2021		2020		2021		2020
	(100)		(70)		(77)		(57)		(0.10)		(0.08)
			(53)				(43)				(0.06)
	<u> </u>						(19)				(0.02)
\$	(100)	\$	(123)	\$	(77)	\$	(119)	\$	(0.10)	\$	(0.16)
	(135)		(179)		(107)		(143)		(0.14)		(0.19)
	(155)		(17)		(107)		. ,		(0.14)		0.04
¢	(125)	¢	(170)	¢	(107)	¢		¢	(0.14)	¢	
\$	(155)	\$	(179)	\$	(107)	2	(114)	2	(0.14)	\$	(0.15)
	(26)		(49)		(18)		(27)		(0.03)		(0.04)
	47		_		35				0.05		_
\$	21	\$	(49)	\$	17	\$	(27)	\$	0.02	\$	(0.04)
	(28)		(37)		(23)		(32)		(0.03)		(0.04)
	60				45				0.06		_
	(54)				(40)				(0.05)		0.24
	_		—		9		182		0.01		—
\$	(22)	\$	(37)	\$	(9)	\$	150	\$	(0.01)	\$	0.20
	\$ \$ \$	2021 (100) — (100) (100) (135) — (135) (135	(100)	2021 2020 (100) (70) - (53) - - § (100) § (135) (123) (135) (179) - - § (135) (135) (179) - - \$ (135) (26) (49) 47 - \$ 21 \$ (49) 47 - (28) (37) 60 - (54) - - -	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	2021 2020 2021 (100) (70) (77) - (53) - - - - $\frac{100}{5}$ $\frac{123}{5}$ $\frac{5}{77}$ $\frac{(135)}{-}$ $\frac{(179)}{-}$ $\frac{(107)}{-}$ $\frac{(135)}{-}$ $\frac{(179)}{5}$ $\frac{(107)}{-}$ $\frac{(26)}{-}$ $\frac{(49)}{-}$ $\frac{(18)}{-}$ $\frac{47}{-}$ - 35 $\frac{$21}{5}$ $\frac{$(49)}{5}$ $\frac{$17}{-}$ (28) (37) (23) 60 - 45 (54) - (40) - - 9	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	2021 2020 2021 2020 (100) (70) (77) (57) - (53) - (43) - - (19) § (100) § (123) § (77) § (119) § (100) § (123) § (77) § (119) (135) (179) (107) (143) - - - 29 § (135) (179) § (107) § (114) (26) (49) (18) (27) § (114) (26) (49) § 17 § (27) 47 - 35 - - § (27) \$ 21 § (37) (23) (32) (32) 60 - 45 - - - - - (28) (37) (23) (32) - - <td>2021 2020 2021 2020 (100) (70) (77) (57) - (53) - (43) - - (19) \$ \$ (100) \$ (123) \$ (77) \$ (119) \$ (135) (179) (107) (143) - - - 29 \$ \$ (135) \$ (179) \$ (107) \$ (114) \$ (26) (49) \$ (18) (27) \$ 47 - 35 - \$ \$ 211 \$ (49) \$ 177 \$ (27) \$ (28) (37) (23) (32) \$ (28) (37) (23) (32) \$ (54) - (40) - - 9 182</td> <td>2021 2020 2021 2020 2021 (100) (70) (77) (57) (0.10) - (53) - (43) - - - (19) - (19) - \$ (100) \$ (123) \$ (77) \$ (119) \$ (0.10) (135) (179) (107) (143) (0.14) - - - - - - 29 - <</td> <td>2021 2020 2021 2020 2021 <t< td=""></t<></td>	2021 2020 2021 2020 (100) (70) (77) (57) - (53) - (43) - - (19) \$ \$ (100) \$ (123) \$ (77) \$ (119) \$ (135) (179) (107) (143) - - - 29 \$ \$ (135) \$ (179) \$ (107) \$ (114) \$ (26) (49) \$ (18) (27) \$ 47 - 35 - \$ \$ 211 \$ (49) \$ 177 \$ (27) \$ (28) (37) (23) (32) \$ (28) (37) (23) (32) \$ (54) - (40) - - 9 182	2021 2020 2021 2020 2021 (100) (70) (77) (57) (0.10) - (53) - (43) - - - (19) - (19) - \$ (100) \$ (123) \$ (77) \$ (119) \$ (0.10) (135) (179) (107) (143) (0.14) - - - - - - 29 - <	2021 2020 2021 2020 2021 <t< td=""></t<>

 Fourth quarter, third quarter, second quarter, and first quarter 2021 included restructuring and asset related (charges), net of \$(28), \$(26), \$(135) and \$(100), respectively. The charges for the fourth quarter primarily relate to a \$(40) charge associated with the 2021 Restructuring Actions, and a \$13 benefit associated with other restructuring programs. The charges for the third quarter primarily relate to a \$(17) charge associated with the 2021 Restructuring Actions and a \$(5) charge related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. The charges for the second quarter primarily relate to a \$(21) charge associated with the 2021 Restructuring Actions and a \$(112) charge related to non-cash

A-11 Corteva, Inc. Significant Items (Dollars in millions, except per share amounts)

2. accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. The charges for the first quarter primarily relate to a \$(89) charge associated with the 2021 Restructuring Actions and a \$(7) charge related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits.

Fourth quarter, third quarter, second quarter and first quarter 2020 included restructuring and asset related charges of \$(37), \$(49), \$(179) and \$(70), respectively. The charge for the fourth quarter included a \$(42) charge related to the Execute to Win Productivity Program, a \$(1) charge related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits, and a \$6 benefit associated with the DowDuPont Synergy Program. The charge for the third quarter included a \$(30) charge related to the Execute to Win Productivity Program, a \$(10) charge related to non-cash accelerated to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits, and a \$6 benefit associated with the DowDuPont Synergy Program. The charge for the third quarter included a \$(30) charge related to the Execute to Win Productivity Program, a \$(10) charge related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits, and a \$(138) charge related to non-cash accelerated prepaid royalty amortization expense related to the Execute to Win Productivity Program. The charge for the second quarter included a \$(41) charge related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. The charge for the first quarter included a \$(63) charge related to the Execute to Win Productivity Program, a \$(10) charge related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. The charge for the first quarter included a \$(63) charge related to the Execute to Win Productivity Program, a \$(10) charge related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits, and a \$3 asset related benefit associated with the DowDuPont Synergy Program.

- 2. First quarter 2020 included a loss of \$(53) included in other income net related to the sale of the La Porte site, for which the Company signed an agreement during the first quarter 2020, and closed during the first quarter of 2021.
- 3. Fourth quarter 2021 included a net benefit for the impact of changes in valuation allowances recorded against the net deferred tax asset positions of two legal entities in Brazil in the amounts of \$57 and \$(44), as well as an adjustment related to the impacts of Swiss Tax Reform of \$(4). Second quarter 2020 reflected a benefit of \$29 due to an elective change in accounting method that altered the 2019 impact of the business separation on the 2017 Tax Cuts and Jobs Act's foreign tax provisions. First quarter 2020 included an after tax charge related to the impact of a state tax valuation allowance in the U.S. based on a change in judgment about the realizability of a deferred tax asset.
- 4. Third quarter 2021 included a benefit relating to a \$47 mark-to-market gain on equity securities.
- 5. Fourth quarter 2021 included a benefit of \$60 relating to the Employee Retention Credit that the Company earned pursuant to the Coronavirus Aid, Relief, and Economic Security ("CARES") Act and enhanced by the Consolidated Appropriations Act ("CAA") and American Rescue Plan Act ("ARPA").
- 6. Fourth quarter 2021 included a charge of \$(54) relating to a contract termination with a third-party service provider.
- 7. Earnings per share for the year may not equal the sum of quarterly earnings per share due to the changes in average share calculations.
- 8. Unless specifically addressed in notes above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

A-12

Corteva, Inc. Reconciliation of Non-GAAP Measures

(Dollars in millions, except per share amounts)

Operating Earnings (Loss) Per Share (Non-GAAP)

Operating earnings (loss) per share is defined as earnings (loss) per share from continuing operations – diluted, excluding non-operating (benefits) costs, amortization of intangibles (existing as of Separation) and significant items.

	_			Three Moi Decem				
	2021			2020		2021		2020
	\$			\$		EPS (diluted)		S (diluted)
Net income (loss) from continuing operations attributable to Corteva (GAAP)	\$	153	\$	97	\$	0.21	\$	0.13
Less: Non-operating benefits (costs), after tax ¹		239		57		0.33		0.08
Less: Amortization of intangibles (existing as of Separation), after tax		(139)		(141)		(0.19)		(0.19)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax ²		2						
Less: Significant items benefit (charge), after tax		(9)		150		(0.01)		0.20
Operating Earnings (Loss) (Non-GAAP)	\$	60	\$	31	\$	0.08	\$	0.04

	Twelve Months Ended December 31,										
		2021		2020		2021		2020			
		\$		\$	EPS	(diluted)	EP	S (diluted)			
Net income (loss) from continuing operations attributable to Corteva (GAAP)	\$	1,812	\$	736	\$	2.44	\$	0.98			
Less: Non-operating benefits (costs), after tax ¹		955		237		1.29		0.32			
Less: Amortization of intangibles (existing as of Separation), after tax		(562)		(518)		(0.76)		(0.69)			
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax 2		_				_					
Less: Significant items benefit (charge), after tax		(176)		(110)		(0.24)		(0.15)			
Operating Earnings (Loss) (Non-GAAP)	\$	1,595	\$	1,127	\$	2.15	\$	1.50			

1. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) benefits (costs), tax indemnification adjustments, environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont, and the 2021 officer indemnification payment. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense.

 Effective January 1, 2021, on a prospective basis, the Company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. For the three and twelve months ended December 31, 2020, the unrealized mark-to-market loss was \$19 and \$0, respectively.

A-13 Corteva, Inc. Operating EBITDA to Operating Earnings (Loss) Per Share (Dollars in millions, except per share amounts)

Operating EBITDA to Operating Earnings (Loss) Per Share

	Three Mo Decen		Twelve Mor Deceml			
	2021	2020	2021	2,576 2,		
Operating EBITDA (Non-GAAP) ¹	\$ 262	\$ 236	 2,576		2,087	
Depreciation	(138)	(128)	(521)		(495)	
Interest Income	19	18	77		56	
Interest Expense	(8)	(10)	(30)		45	
Provision for income taxes on continuing operations before significant items, non-operating (benefits) charges, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses) (Non-GAAP) ¹	(43)	(46)	(409)		(295)	
Base income tax rate from continuing operations (Non-GAAP) ¹	31.9 %	39.7 %	19.5 %		18.4 %	
Exchange gains (losses), after tax ²	(30)	(37)	(88)		(161)	
Net income (loss) attributable to non-controlling interests	(2)	(2)	(10)		(20)	
Operating Earnings (Loss) (Non-GAAP) ¹	\$ 60	\$ 31	\$ 1,595	\$	1,217	
Diluted Shares (in millions)	735.1	749.7	741.6		751.2	
Operating Earnings (Loss) Per Share (Non-GAAP) ¹	\$ 0.08	\$ 0.04	\$ 2.15	\$	1.50	

1. Refer to pages A-5 through A-9, and A-12 and A-14 for Non-GAAP reconciliations.

2. Refer to page A-15 for pre-tax and after tax impacts of exchange gains (losses) - net.

A-14 Corteva, Inc. Reconciliation of Non-GAAP Measures (Dollars in millions, except per share amounts)

Reconciliation of Base Income Tax Rate to Effective Income Tax Rate

Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), significant items, amortization of intangibles (existing as of Separation), and non-operating benefits (costs).

Add:Significant items (benefit) charge 12237236388Non-operating (benefit) costs (315) (79) $(1,256)$ (316) Amortization of intangibles (existing as of Separation)179181722 682 Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges 2 (3) $$ (174) Icess:Exchange gains (losses) 3 (7) (47) (54) (174) Income (loss) from continuing operations before income taxes, significant times, non-operating benefits - net, anortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP)\$135\$\$169\$<		 Three Mo Decem			Twelve Mo Decem		
Add:Significant items (benefit) charge 12237236388Add:Significant items (benefit) charge 12237236388Non-operating (benefit) costs(315)(79)(1,256)(316)Amortization of intangibles (existing as of Separation)179181722682Mark-to-market (gains) losses on certain foreign currency contracts(3)Less:Exchange gains (losses) 3(7)(47)(54)(174)Income (loss) from continuing operations before income taxes, significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency\$135\$116\$2,102\$1,603Provision for (benefit from) provision for income taxes on continuing operations (GAAP)\$90\$(169)\$524\$(81)Add:Tax benefits on micrization of intangibles (existing as of Separation)4040160164164Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges?(1)Tax benefits on mark-to-market gains) losses on certain foreign currency curr		2021		2020	2021		2020
Non-operating (benefits) costs(315)(79)(1,256)(316)Amortization of intangibles (existing as of Separation)179181722682Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges 2 (3)Less: Exchange gains (losses) 3 (7)(47)(54)(174)Income (loss) from continuing operations before income taxes, significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP)S135S116S2,102S1,603Provision for (benefit from) provision for income taxes on continuing operations (GAAP)S90S(169)S524\$(81)Add: Tax benefits on significant items charge 113187602781318760278Tax benefits on amortization of intangibles (existing as of Separation)4040160164Tax benefits on amark-to-market gains on certain foreign currency contracts not designated as hedges, net2(23)10(34)13Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non- 	Income (loss) from continuing operations before income taxes (GAAP)	\$ 245	\$	(70)	\$ 2,346	\$	675
Amotization of intangibles (existing as of Separation)179181722682Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges 2^{\pm} (3)——Less:Exchange gains (losses) 3 (7)(47)(54)(174)Income (loss) from continuing operations before income taxes, significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP)S135S116S2,102S1,603Provision for (benefit from) provision for income taxes on continuing operations (GAAP)S90S(169)S524S(81)Add: Tax benefits on significant items charge!13187602782781318760278Tax copenses on non-operating benefits - net(76)(22)(301)(79)1314040160164Tax benefits on significant items charge?(1)—————Tax benefits on exchange losses, net?(23)10(34)13Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amotization of intangibles 	Add: Significant items (benefit) charge ¹	22		37	236		388
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges 2 (3)Less: Exchange gains (losses) 3 (7)(47)(54)(174)Income (loss) from continuing operations before income taxes, significant titems, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP)\$135\$116\$2,102\$1,603Provision for (benefit from) provision for income taxes on continuing operations (GAAP)\$90\$(169)\$524\$(81)Add: Tax benefits on significant items charge 11318760278278\$160164Tax expenses on non-operating benefits - net(76)(22)(301)(79)13160164Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges?10Tax benefits on exchange losses, net2(23)10(34)13Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (10)Effective income tax rate (GAAP)36.7 %241.4 %22.3 %(12.0)%Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-mar	Non-operating (benefits) costs	(315)		(79)	(1,256)		(316)
not designated as hedges 2 (3)Less: Exchange gains (losses) 3 (7)(47)(54)(174)Income (loss) from continuing operations before income taxes, significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP)\$135\$116\$2,102\$1,603Provision for (benefit from) provision for income taxes on continuing operations (GAAP)\$90\$(169)\$524\$(81)Add: Tax benefits on significant items charge 1131876027827813318760278Tax expenses on non-operating benefits - net(76)(22)(301)(79)134160164Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges2(1)Tax benefits on exchange losses, net2(23)10(34)13Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non- GAAP)\$43\$46\$409\$295Effective income tax rate (GAAP)36.7 %241.4 %(18.9.2)%(0.7)%31.7 %Significant items, non-operating benefits, and amortization of intangibles (existing as of Sep	Amortization of intangibles (existing as of Separation)	179		181	722		682
Income (loss) from continuing operations before income taxes, significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP) $\frac{1}{35}$ $\frac{1}{35}$ $\frac{1}{16}$ $\frac{1}{5}$ $\frac{2}{2,102}$ $\frac{1}{5}$ $\frac{1}{603}$ Provision for (benefit from) provision for income taxes on continuing operations (GAAP) $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{60}$ $\frac{1}{278}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{60}$ $\frac{1}{278}$ $\frac{1}{1}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{60}$ $\frac{1}{278}$ $\frac{1}{1}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{60}$ $\frac{1}{278}$ $\frac{1}{1}$ $\frac{1}{32}$ $\frac{1}{30}$ $\frac{1}{30}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{30}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{30}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{31}$ $\frac{1}{30}$ $\frac{1}{31}$ $\frac{1}$		(3)			—		
items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP) $\frac{1}{35}$ $\frac{1}{35}$ $\frac{1}{16}$ $\frac{5}{2}$ $\frac{2,102}{5}$ $\frac{5}{1,603}$ Provision for (benefit from) provision for income taxes on continuing operations (GAAP) $\frac{5}{90}$ $\frac{5}{6}$ (169) $\frac{5}{524}$ $\frac{5}{6}$ (81) Add: Tax benefits on significant items charge ¹ 13 187 60 278 Tax expenses on non-operating benefits - net (76) (22) (301) (79) Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges ² (1) Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges ² (23) 10 (34) 13 Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non- GAAP) $\frac{5}{43}$ $\frac{46}{5}$ $\frac{409}{5}$ $\frac{5}{295}$ Effective income tax rate (GAAP) $\frac{36.7 \%}{241.4 \%}$ $\frac{241.4 \%}{22.3 \%}$ (12.0)% Significant items, non-operating benefits, and amortization of intangibles foreign currency contracts not designated as hedges effect $\frac{14.4 \%}{14.4 \%}$ (189.2)% (0.7)% $\frac{31.7 \%}{31.7 \%}$ Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles foreign currency contracts not designated as hedges effect $\frac{14.4 \%}{14.4 \%}$ $\frac{52.2 \%}{12.6 \%}$ $\frac{21.6 \%}{19.7 \%}$ Exchange losses, net effect ³ (12.3)% (12.3)% (2.2)% (1.3)%	Less: Exchange gains (losses) ³	(7)		(47)	(54)		(174)
s90\$(169)\$524\$(81)Add: Tax benefits on significant items charge!1318760278Tax expenses on non-operating benefits - net(76)(22)(301)(79)Tax benefits on amortization of intangibles (existing as of Separation)4040160164Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges ² (1)Tax benefits on exchange losses, net ² (23)10(34)13Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non- GAAP) $$ 43$ \$ 46\$ 409\$ 295Effective income tax rate (GAAP) $$ 36.7$ % $$ 241.4$ % $$ 22.3$ % $$ (12.0)$ %Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect $$ 43$ \$ 46\$ 409\$ 295Tax rate from continuing operations before significant items, non-operating benefits, existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect $$ 14.4$ % $$ (189.2)$ % $$ (0.7)$ % $$ 31.7$ %Tax rate from continuing operations before significant items, non-operating benefits, net, and amortization of intangibles (existing as of Separation), and <b< td=""><td>Income (loss) from continuing operations before income taxes, significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP)</td><td>135</td><td>\$</td><td>116</td><td>\$ 2,102</td><td>\$</td><td>1,603</td></b<>	Income (loss) from continuing operations before income taxes, significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP)	135	\$	116	\$ 2,102	\$	1,603
Tax expenses on non-operating benefits - net(76)(22)(301)(79)Tax benefits on amortization of intangibles (existing as of Separation)4040160164Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges²(1)Tax benefits on exchange losses, net²(23)10(34)13Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non- GAAP)S43S46S409S295Effective income tax rate (GAAP)36.7 %241.4 %22.3 %(12.0)%Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect14.4 %(189.2)%(0.7)%31.7 %Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect14.4 %(189.2)%(0.7)%31.7 %Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP)51.1 %52.2 %21.6 %1	Provision for (benefit from) provision for income taxes on continuing operations (GAAP)	\$ 90	\$	(169)	\$ 524	\$	(81)
Tax benefits on amortization of intangibles (existing as of Separation) Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges ² 4040160164Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges ² (1)Tax benefits on exchange losses, net ² (23)10(34)13Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non- 	Add: Tax benefits on significant items charge ¹	13		187	60		278
Tax benefits on mark-to-market gains on certain foreign currency contracts not designated as hedges ² (1) — Tax benefits on exchange losses, net ² (23) 10 (34) 13 Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP) \$ 43 \$ 46 \$ 409 \$ 295 Effective income tax rate (GAAP) 36.7 % 241.4 % 22.3 % (12.0)% Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect 14.4 % (189.2)% (0.7)% 31.7 % Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect 14.4 % (189.2)% (0.7)% 31.7 % Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP) 51.1 % 52.2 % 21.6 % 19.7 % Exchange loss	Tax expenses on non-operating benefits - net	(76)		(22)	(301)		(79)
contracts not designated as hedges2(1)Tax benefits on exchange losses, net2(23)10(34)13Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non- GAAP)\$43\$46\$409\$295Effective income tax rate (GAAP)36.7 %241.4 %22.3 %(12.0)%Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect14.4 %(189.2)%(0.7)%31.7 %Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect14.4 %(189.2)%(0.7)%31.7 %Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP)51.1 %52.2 %21.6 %19.7 %Exchange losses, net effect ³ (19.3)%(12.5)%(2.2)%(1.3)%	Tax benefits on amortization of intangibles (existing as of Separation)	40	_	40	160	_	164
Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non- GAAP) Effective income tax rate (GAAP) Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP) Exchange losses, net effect ³ (19.3)% (12.5)% (2.2)% (1.3)%		(1)			—		
significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non- GAAP) <u>\$ 43 \$ 46 \$ 409 \$ 295</u> Effective income tax rate (GAAP) <u>36.7 % 241.4 % 22.3 % (12.0)%</u> Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect <u>14.4 % (189.2)% (0.7)% 31.7 %</u> Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP) <u>51.1 % 52.2 % 21.6 % 19.7 %</u> Exchange losses, net effect ³ (19.3)% (12.5)% (2.2)% (1.3)%	Tax benefits on exchange losses, net ²	(23)		10	(34)	_	13
Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect 14.4 % (189.2)% (0.7)% 31.7 % Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP) 51.1 % 52.2 % 21.6 % 19.7 % Exchange losses, net effect ³ (19.3)% (12.5)% (2.2)% (1.3)%	Provision for (benefit from) income taxes on continuing operations before significant items, non-operating benefits - net, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange losses, net (Non-GAAP)	\$ 43	\$	46	\$ 409	\$	295
Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect 14.4 % (189.2)% (0.7)% 31.7 % Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP) 51.1 % 52.2 % 21.6 % 19.7 % Exchange losses, net effect ³ (19.3)% (12.5)% (2.2)% (1.3)%							
(existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect14.4 % (189.2)% (0.7)% 31.7 %Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP)51.1 % 52.2 % 21.6 % 19.7 %Exchange losses, net effect ³ (19.3)% (12.5)% (2.2)% (1.3)%	Effective income tax rate (GAAP)	36.7 %		241.4 %	22.3 %		(12.0)%
benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP) Exchange losses, net effect ³ (19.3)% (12.5)% (2.2)% (1.3)%	Significant items, non-operating benefits, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect	14.4 %		(189.2)%	(0.7)%		31.7 %
	Tax rate from continuing operations before significant items, non-operating benefits - net, and amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (Non-GAAP)	51.1 %		52.2 %	21.6 %		19.7 %
Base income tax rate from continuing operations (Non-GAAP) 31.9 % 39.7 % 19.5 % 18.4 %	Exchange losses, net effect ³	(19.3)%		(12.5)%	(2.2)%		(1.3)%
	Base income tax rate from continuing operations (Non-GAAP)	 31.9 %		39.7 %	 19.5 %		18.4 %

1. See page A-10 for further detail on the Significant Items table.

2. Effective January 1, 2021, on a prospective basis, the Company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. For the three and twelve months ended December 31, 2020, the unrealized mark-to-market loss was \$19 and \$0, respectively.

3. See page A-15 for further details of exchange gains (losses).

A-15 Corteva, Inc. (Dollars in millions, except per share amounts)

Exchange Gains/Losses

The Company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currencydenominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the United States (U.S.), whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the Consolidated Statements of Operations.

	Three Mor Decem			Ended 31,		
	2021	 2020		2021		2020
Subsidiary Monetary Position Gain (Loss)						
Pre-tax exchange gains (losses)	\$ (25)	\$ 37	\$	(72)	\$	(263)
Local tax (expenses) benefits	 (19)	(10)		(30)		34
Net after tax impact from subsidiary exchange gains (losses)	\$ (44)	\$ 27	\$	(102)	\$	(229)
<u>Hedging Program (Loss) Gain</u>						
Pre-tax exchange (losses) gains	\$ 18	\$ (84)	\$	18	\$	89
Tax benefits (expenses)	 (4)	 20		(4)		(21)
Net after tax impact from hedging program exchange (losses) gains	\$ 14	\$ (64)	\$	14	\$	68
<u>Total Exchange Gain (Loss)</u>						
Pre-tax exchange gains (losses)	\$ (7)	\$ (47)	\$	(54)	\$	(174)
Tax benefits (expenses)	(23)	 10		(34)		13
Net after tax exchange gains (losses)	\$ (30)	\$ (37)	\$	(88)	\$	(161)

As shown above, the "Total Exchange Gain (Loss)" is the sum of the "Subsidiary Monetary Position Gain (Loss)" and the "Hedging Program (Loss) Gain."